Bexagliflozin – evaluation of the clinical efficacy, safety profile and potential new applications of the SGLT2 inhibitor: a review of the literature

Józef Muszyński

doi:10.20883/medical.e1226

Authors

Józef Muszyński Dr. Jan Jonston Regional Multispecialty Hospital in Leszno, Poland https://orcid.org/0009-0000-7229-4747

DOI:

https://doi.org/10.20883/medical.e1226

Keywords:

flozin, bexagliflozin, EGT1442

Abstract

Introduction. Type 2 diabetes (T2DM) is a growing global health, social, and economic problem. T2DM is often accompanied by other diseases and is associated with complications such as kidney damage and cardiovascular diseases. The 21st century has seen a breakthrough in treating T2DM, including incretins and flozins. This review focuses on bexagliflozin, a new SGLT-2 inhibitor approved by the FDA for treating T2DM. The efficacy, safety, and potential benefits of new uses are analysed.

Materials and methods. Sources were obtained using PubMed and Google Scholar, as well as Medline, with the keywords: bexagliflozin, EGT1442, new indications for bexagliflozin, and bexagliflozin trials.

Results. Unlike other SGLT-2 inhibitors, bexagliflozin has a different molecular structure, which may increase its selectivity and efficacy. Preliminary results suggest that the drug may offer additional therapeutic benefits over other drugs in this group, particularly in the treatment of hypertension and cardiac arrhythmias. Studies are currently underway to investigate its potential use in the treatment of chronic kidney disease in children and sleep apnoea.

Conclusions. Bexagliflozin shows promise as a treatment for type 2 diabetes, with additional potential benefits in treating other conditions. Although the drug is relatively new to the market, preliminary studies indicate that it may offer advantages over other SGLT-2 inhibitors in some areas. Nevertheless, further clinical trials are needed to further evaluate its efficacy compared to other therapies and its potential in a broader range of applications

Downloads

Download data is not yet available.

References

Tentolouris A, Vlachakis P, Tzeravini E, Eleftheriadou I, Tentolouris N. SGLT2 inhibitors: a review of their antidiabetic and cardioprotective effects. International journal of environmental research and public health. 2019 Aug;16(16):2965. https://doi.org/10.3390/ijerph16162965.

Bassett RL, Gallo G, Le KP, Volino LR. Bexagliflozin: a comprehensive review of a recently approved SGLT2 inhibitor for the treatment of type 2 diabetes mellitus. Medicinal Chemistry Research. 2024 Aug;33(8):1354-67. https://doi.org/10.3390/ijerph16162965.

Celik S, Er A. Molecular docking studies of antidiabetic compounds with DPPIV protease. New Approaches in Science and Engineering. 2023;23. Available from: https://artikelakademi.com/media/books/227b11947be2441d9837d7955953e3bb.pdf#page=23.

Europe PMC. Europe PMC. Available from: https://europepmc.org/books/nbk581934.

Zhu R, Zhou S, Xia L, Bao X. Incidence, morbidity and years lived with disability due to type 2 diabetes mellitus in 204 countries and territories: trends from 1990 to 2019. Frontiers in endocrinology. 2022 Jul 11;13:905538. https://doi.org/10.3389/fendo.2022.905538.

Stachteas P, Patoulias D, Popovic DS, Athanasiadou P, Fragakis N. Bexagliflozin as an Adjunct Therapy to Diet and Exercise to Improve Glycaemic Control in Adults with Type 2 Diabetes. touchREVIEWS in Endocrinology. 2023 Dec 19;20(1):19. https://doi.org/10.17925/ee.2024.20.1.6.

Papatheodorou K, Banach M, Bekiari E, Rizzo M, Edmonds M. Complications of diabetes 2017. Journal of diabetes research. 2018;2018. https://doi.org/10.1155/2018/3086167.

Jasleen B, Vishal GK, Sameera M, Fahad M, Deion S, Pemminati S. Sodium-glucose cotransporter 2 (SGLT2) inhibitors: benefits versus risk. Cureus. 2023 Jan;15(1). https://doi.org/10.7759/cureus.33939.

Kurczyński D, Hudzik B, Jagosz M, Zabierowski J, Nowak J, Tomasik A, Badziński A, Rozentryt P, Gąsior M. Sodium-Glucose Cotransporter-2 Inhibitors-from the Treatment of Diabetes to Therapy of Chronic Heart Failure. Journal of Cardiovascular Development and Disease. 2022 Jul 14;9(7):225. https://doi.org/10.3390/jcdd9070225.

Giruzzi M, Worthey A. Bexagliflozin. Clinical Diabetes. 2024 Jan 1;42(1):169-71. https://doi.org/10.2337/cd23-0085.

Papapetropoulos A, Topouzis S, Alexander SP, Cortese-Krott M, Kendall DA, Martemyanov KA, Mauro C, Nagercoil N, Panettieri Jr RA, Patel HH, Schulz R. Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review. British Journal of Pharmacology. 2024 Jun;181(11):1553-75. https://doi.org/10.1111/bph.16337.

Elanco. Elanco announces FDA approval of Bexacat™ (bexagliflozin tablets) – the first-of-its-kind oral feline diabetes treatment option. @Elanco. Published 2020. Accessed January 9, 2025.

Dalal D, Kant R, Attri K, Kapoor G, Nagarajan K, Bhutani R, Sharma K, Kaushik U, Yadav M, Jamwal NS. A Systematic Overview of Bexagliflozin: A Type 2 Diabetic Drug. Asian Journal of Pharmaceutical Research and Health Care. 2023 Apr 1;15(2):109-14. https://doi.org/10.4103/ajprhc.ajprhc_25_23.

Fathi A, Vickneson K, Singh JS. SGLT2-inhibitors; more than just glycosuria and diuresis. Heart failure reviews. 2021 May;26(3):623-42. https://doi.org/10.1007/s10741-020-10038-w.

Hoy SM. Bexagliflozin: first approval. Drugs. 2023 Apr;83(5):447-53.doi:10.1007/s40265-023-01848-x.

France NL, Shirley M. Bexagliflozin in type 2 diabetes: a profile of its use. Drugs & Therapy Perspectives. 2024 Jul;40(7):241-9.https://doi.org/10.1007/s40267-024-01098-1.

Highlights of prescribing information. Available from: https://brenzavvy.com/wp-content/uploads/2023/10/Brenzavvy-Prescribing-Information-PI-001-09_FINAL.pdf.

Halvorsen YD, Walford G, Thurber T, Russell H, Massaro M, Freeman MW. A 12-week, randomized, double-blind, placebo-controlled, four-arm dose-finding phase 2 study evaluating bexagliflozin as monotherapy for adults with type 2 diabetes. Diabetes, Obesity and Metabolism. 2020 Apr;22(4):566-73.https://doi.org/10.1111/dom.13928.

Halvorsen YD, Walford GA, Massaro J, Aftring RP, Freeman MW. A 96-week, multinational, randomized, double-blind, parallel-group, clinical trial evaluating the safety and effectiveness of bexagliflozin as a monotherapy for adults with type 2 diabetes. Diabetes, Obesity and Metabolism. 2019 Nov;21(11):2496-504. https://doi.org/10.1111/dom.13833.

Halvorsen YD, Conery AL, Lock JP, Zhou W, Freeman MW. Bexagliflozin as an adjunct to metformin for the treatment of type 2 diabetes in adults: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes, Obesity and Metabolism. 2023 Oct;25(10):2954-62. https://doi.org/10.1111/dom.15192.

Xie L, Han J, Cheng Z, Liu D, Liu J, Xu C, Sun W, Li Q, Bian F, Zhang W, Chen J. Efficacy and safety of bexagliflozin compared with dapagliflozin as an adjunct to metformin in Chinese patients with type 2 diabetes mellitus: A 24-week, randomized, double-blind, active-controlled, phase 3 trial. Journal of Diabetes. 2024 Apr;16(4):e13526. https://doi.org/10.1111/1753-0407.13526.

Halvorsen YD, Lock JP, Frias JP, Tinahones FJ, Dahl D, Conery AL, Freeman MW. A 96-week, double-blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults. Diabetes, Obesity and Metabolism. 2023 Jan;25(1):293-301.https://doi.org/10.1111/dom.14875.

Halvorsen YD, Lock JP, Zhou W, Zhu F, Freeman MW. A 24-week, randomized, double-blind, active-controlled clinical trial comparing bexagliflozin with sitagliptin as an adjunct to metformin for the treatment of type 2 diabetes in adults. Diabetes, Obesity and Metabolism. 2019 Oct;21(10):2248-56. https://doi.org/10.1111/dom.13801.

Halvorsen YD, Walford GA, Massaro J, Aftring RP, Freeman MW. A 96-week, multinational, randomized, double-blind, parallel-group, clinical trial evaluating the safety and effectiveness of bexagliflozin as a monotherapy for adults with type 2 diabetes. Diabetes, Obesity and Metabolism. 2019 Nov;21(11):2496-504. https://doi.org/10.1111/dom.13833.

McMurray JJ, Solomon SD, Lock JP, Massaro JM, Zhu F, Zhou W, Skali H, Lewis EF, Freeman MW, Halvorsen YD. Meta-analysis of risk of major adverse cardiovascular events in adults with type 2 diabetes treated with bexagliflozin. Diabetes, Obesity and Metabolism. 2024 Mar;26(3):971-9. https://doi.org/10.1111/dom.15394.

Lin J, Wang S, Wen T, Zhang X. Renal protective effect and safety of sodium-glucose cotransporter-2 inhibitors in patients with chronic kidney disease and type 2 diabetes mellitus: a network meta-analysis and systematic review. International Urology and Nephrology. 2022 Sep;54(9):2305-16. https://doi.org/10.1007/s11255-022-03117-4.

CTG Labs - NCBI. ClinicalTrials.gov. Accessed November 22, 2024. Available from: https://clinicaltrials.gov/study/NCT02558296.

Zhang W, Welihinda A, Mechanic J, Ding H, Zhu L, Lu Y, Deng Z, Sheng Z, Lv B, Chen Y, Roberge JY. EGT1442, a potent and selective SGLT2 inhibitor, attenuates blood glucose and HbA1c levels in db/db mice and prolongs the survival of stroke-prone rats. Pharmacological Research. 2011 Apr 1;63(4):284-93. https://doi.org/10.1016/j.phrs.2011.01.001.

ClinicalTrials.gov. Accessed December 4, 2024. Available from: https://clinicaltrials.gov/study/NCT03514641?intr=bexagliflozin&rank=3.

Xu B, Kang B, Zhou J. Sodium glucose cotransporter 2 inhibitors with cardiac arrhythmias in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized placebo-controlled trials. Clinical Research in Cardiology. 2024 Feb 14:1-4. https://doi.org/10.1007/s00392-024-02386-6.

ClinicalTrials.gov. Accessed November 2, 2024. Available from: https://clinicaltrials.gov/study/NCT05612594?intr=bexagliflozin&rank=1.

TheracosBio launches lowest cost SGLT2 inhibitor Brenzavvy. Thepharmaletter.com. Published July 13, 2023. Accessed December 18, 2024. Available from: https://www.thepharmaletter.com/pharmaceutical/theracosbio-launches-lowest-cost-sglt2-inhibitor-brenzavvy.

Ostrominski JW, Solomon SD, Vaduganathan M. Heart failure with preserved ejection fraction therapy: combining sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists. European Heart Journal. 2024 Aug 7;45(30):2748-51. https://doi.org/10.1093/eurheartj/ehae414.